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Abstract 37 
Background  38 
Alzheimer’s disease (AD) is a neurodegenerative condition where the underlying aetiology is 39 
still unclear. Investigating the potential influence of apolipoprotein e (APOE), a major genetic 40 
risk factor, on common blood biomarkers could provide a greater understanding of the 41 
mechanisms of AD and dementia risk.  42 
Objective  43 
Our objective was to conduct the largest (to date) single-protocol investigation of blood 44 
biomarkers in the context of APOE genotype, in UK Biobank. 45 
Methods  46 
After quality control and exclusions, data on 395,769 participants of White European ancestry 47 
were available for analysis. Linear regressions were used to test potential associations between 48 
APOE genotypes and biomarkers. 49 
Results 50 
Several biomarkers significantly associated with APOE e4 ‘risk’ and e2 ‘protective’ genotypes 51 
(vs. neutral e3/e3). Most associations supported previous data: for example, e4 genotype was 52 
associated with elevated low-density lipoprotein cholesterol (LDL) (standardized beta [b] = 53 
0.150 standard deviations [SDs] per allele, p<0.001) and e2 with lower LDL (b = -0.456 SDs, 54 
p<0.001). There were however instances of associations found in unexpected directions: e.g. e4 55 
and increased insulin-like growth factor (IGF-1) (standardized beta = 0.017, p<0.001) where 56 
lower levels have been previously suggested as an AD risk factor.  57 
Conclusion 58 
These findings highlight biomarker differences in non-demented people at genetic risk for 59 
dementia. The evidence here in supports previous hypotheses of involvement from 60 
cardiometabolic and neuroinflammatory pathways.  61 
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Introduction 62 
Alzheimer disease (AD) is the most common form of dementia and an important public health 63 
issue [1], hypothesized to be the result of interactions between genetic and environmental risk 64 
factors [2]. APOE e4 genotype is the largest common single genetic risk factor for AD and 65 
cognitive decline behind increasing age [3], with the e2 allele potentially protective [1]. The 66 
exact mechanisms by which APOE genotype influences brain ageing are unclear but probably 67 
due to pleiotropic pathways stemming from its core role in lipid metabolism [4]. 68 
Several studies have investigated serum biomarker differences between AD patients vs. 69 
healthy individuals in order to identify potential risk factors, including low density lipoproteins 70 
(LDL) and insulin-like growth factor 1 (IGF-1) with sometimes conflicting results potentially 71 
due to methodological heterogeneity [5,6]. Many studies investigating serum levels in AD have 72 
focussed on specific biomarkers involved in β-amyloid precursor protein metabolism and 73 
phosphorylation [7]. There have been relatively few studies investigating a wide range of 74 
biomarkers in a “hypothesis-free” approach; and those studies which have done this appear to 75 
be limited by small sample size or have been cross-sectional in individuals with an extant 76 
diagnosis of dementia [8–10]. Relatively few biomarkers have been investigated in the context 77 
of AD-susceptibility gene APOE. Gaining a greater understanding of how APOE influences 78 
biomarker serum levels could be extremely beneficial: highlighting factors significantly 79 
associated with AD genetic risk could elucidate potential pathways involved in its development, 80 
pathophysiology and ultimately treatment [11].  81 
In this study APOE genotype status was tested vs. a range of circulating serum blood 82 
biomarkers available for approximately 396,000 participants in UK Biobank. Two separate 83 
analyses were undertaken to investigate the influence of genotypic status on biomarker levels: 84 
differences per i) risk e4, or ii) protective e2 allele; each vs. neutral e3/e3 genotype. Further 85 
analyses were undertaken to investigate the associations in males and females separately due to 86 
a priori evidence for APOE-sex differences in AD pathophysiology [12]. To our knowledge, this is 87 
the first large-scale investigation of the relationship between APOE genotype status and a wide 88 
range of biomarkers in a population cohort. 89 
 90 
Methods 91 
Subjects 92 
Over 502,000 UK residents aged 37-73 years were recruited to UK Biobank from 2006-2010. At 93 
one of 22 assessment centres across the UK, participants completed a range of phenotypic 94 
assessments and questionnaires, including genetic, urine and blood samples [13]. We focussed 95 
on participants with White British ancestry because there is evidence of different e4 frequencies 96 
across ethnicities[14].   97 
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Ethical approval 98 
This secondary-data analysis study was conducted under generic approval from the NHS 99 
National Research Ethics Service (approval letter dated 17th June 2011, ref 11/NW/0382). 100 
Written informed consent was obtained from all participants in the study (consent for research, 101 
by UK Biobank). 102 
 103 
Genotyping 104 
UK Biobank participants were genotyped using Applied Biosystems UK BiLEVE Axiom array by 105 
Affymetrix and Applied Biosystems UK Biobank Axiom Array which share 95% marker content 106 
[13]. APOE e status was based on two single nucleotide polymorphisms (SNPs): rs7412 and 107 
rs429358. Stringent quality control and processing were applied to the data, detailed at 108 
http://www.ukbiobank.ac.uk/scientists-3/genetic-data and http://www.ukbiobank.ac.uk/wp-109 
content/uploads/2014/04/UKBiobank_genotyping_QC_documentation-web.pdf.  110 
 111 
Biomarker collection and processing 112 
Biomarker levels were analysed in UK Biobank from serum and packed red blood cell samples 113 
obtained from all UK Biobank participants at baseline [15]. Stringent quality controls were 114 
applied to the assays used measure biomarker levels, details of biomarker quality control, 115 
instrumentation and analysis methods are available at: 116 
https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/biomarker_issues.pdf, 117 
https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.pdf, 118 
http://biobank.ndph.ox.ac.uk/showcase/showcase/docs/haematology.pdf, and 119 
http://www.ukbiobank.ac.uk/wp-120 
content/uploads/2018/11/BCM023_ukb_biomarker_panel_website_v1.0-Aug-2015-edit-121 
2018.pdf. Processing of very low levels of oestradiol and rheumatoid factor (RF) were recorded 122 
as “missing” (in the original data); these missing values were recoded conservatively as the 123 
square root of the minimum stated detectable value if individuals had data for a remaining 124 
biomarker [16] and were not coded as ‘no data returned’ or having unrecoverable aliquot 125 
problems. Oestradiol and RF require attention in this context because they were the biomarkers 126 
highlighted by UK Biobank as the variables with by far the highest frequency of values below 127 
reportable levels (75-90% of results); no assays had >0.1% of results above their reportable 128 
range.  129 
 130 
Dementia outcomes 131 
We validated APOE genotype’s association with dementia/AD outcomes (in UK Biobank) as a 132 
check, having previously shown associations in expected directions with brain structure [3] and 133 
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cognitive abilities [17]. Dementia and AD outcomes were generated using self-report, hospital 134 
admission and death record data, with hospital and death record data utilising International 135 
Classification of Diseases version 10 (ICD-10 codes). Individuals were designated as cases (“all-136 
cause dementia” or “Alzheimer disease”) if they had indicated dementia or AD in either self-137 
report, or through hospital or death records – derived by UK Biobank based on self-report, 138 
hospital admission and death reports [18]. Those coded as missing were designated as controls 139 
(i.e. did not self-report dementia/AD, and these diagnoses were not present in hospital/death 140 
records). 141 
 142 
Covariates 143 
Participants self-reported their smoking history, and we collated past and current smokers into 144 
‘ever’ (vs. never). Participants self-reported medication use for cholesterol, high blood pressure 145 
or insulin. We excluded those who did not know or preferred not to answer for these various 146 
items (<5%). Townsend deprivation indices were derived from postcode of residence [19]. This 147 
provides an area-based measure of socioeconomic deprivation derived from aggregated data on 148 
car ownership, household overcrowding, owner occupation and unemployment. Higher 149 
Townsend scores equate to higher levels of area-based socioeconomic deprivation. We 150 
additionally controlled for potential population stratification using UK Biobank-derived 151 
principal components (PCs) 1-5, and genotypic array[13]. Height was measured (Seca 202 152 
stadiometer) and weight was measured to the nearest 0.1 kg (BC-418 MA body composition 153 
analyser; Tanita Corp). Body mass index (BMI) was derived from weight in kilograms divided by 154 
height in meters squared. All-cause cancer was derived based on self-report at baseline. Month 155 
of assessment was recorded by UK Biobank. We have previously described and derived an ‘any 156 
self-reported inflammatory condition’ variable[20], including 58 conditions described in an 157 
open-access report. Participant assessment centre was recorded by UK Biobank, and 158 
educational attainment was self-reported.  159 
 160 
Statistical analyses 161 
The linear regressions reported reflect average SD-changes per e4 or e2 allele vs. neutral e3/e3 162 
genotype, i.e. e3/e3 vs. e3/e4 vs. e4/e4 (dose), and e2/e2 vs. e2/e3 vs. e3/e3 (dose). 163 
Associations with APOE genotype vs. dementia/AD were tested using binary logistic regressions 164 
reporting odds ratios (OR) and their 95% confidence intervals. We corrected for multiple 165 
testing using False Discovery Rate (FDR)[21], conservatively collating all tests. Biomarkers 166 
which were not normally distributed were log transformed prior to Z-score transformation and 167 
reanalysed: the resulting effect sizes were unchanged and therefore we report the original 168 
estimates. 169 
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Three linear regression models were used to investigate potential associations with 170 
each biomarker and adjusted for potential confounders. Model 1 (‘minimally-adjusted’) adjusted 171 
for age, sex, baseline assessment centre, principal components 1-5 for population stratification, 172 
and genotyping array. Model 2 (‘partially-adjusted’) also included self-reported diabetes, high 173 
blood pressure and coronary heart disease (comprised of angina plus myocardial infarction 174 
[22]). Model 3 (‘fully adjusted’) also controlled for self-reported cholesterol, hormone 175 
replacement therapy, oral contraceptive, insulin or hypertension medication, Townsend 176 
deprivation scores, and ever vs. never smoking. The cross-sectional association between APOE 177 
vs. dementia outcomes were also analysed using these models.  178 
As additional sensitivity analyses we adjusted for dummy-variable ‘any self-reported 179 
chronic inflammatory condition’  (n=64,996; 17%); underweight (BMI<18.5; n=1,962 or 0.5%) 180 
or obesity (BMI≥30, n = 297,738 or 75.4%) vs. normal to overweight (18.5 to 30 BMI; n=95,001 181 
or 24.1%), month of assessment, university/college degree vs. not, and finally we additionally 182 
corrected any significant associations with IGF-1 for self-reported baseline cancer history 183 
(n=33,406; 8%) [23]. SNP data was collated and quality controlled with PLINK V1.90, and 184 
analysed with Stata V16.  185 
 186 
Results 187 
We excluded participants with non-white British ancestry (N=78,672; 16%), sex mismatch (self-188 
report versus genetic), chromosomal aneuploidy, excessive heterozygosity and genotype 189 
missing rate >10%. We excluded the minority of participants with e2/e4 (n=2,556; 0.7%) 190 
genotype because this included potentially protective and risk alleles [24]. We removed outliers 191 
>5SDs from the mean for each biomarker. This left overall N=395,769 which varied slightly by 192 
biomarker: Table 1 shows sample size and key values per biomarker.  193 
 194 
[Table 1 here] 195 
 196 
APOE associations with dementia phenotypes 197 
As a form of replication and to support the utility of investigating APOE genotype in the UK 198 
Biobank cohort, we tested for e4 and e2 allele count (vs. e3/e3) against all-cause dementia 199 
(n=1,852; 0.5%), and specific AD diagnosis (n=722; 0.2%). We found that e4 was associated 200 
with increased AD (fully-adjusted OR = 3.51 per allele, 95% CI = 3.14 to 3.92, P<0.001) and all-201 
cause dementia (OR = 2.59, 95% CI = 2.40 to 2.79, P<0.001), whereas, e2 was correspondingly 202 
associated with decreased AD (OR = 0.59, 95% CI = 0.40 to 0.85, P = 0.005) and all-cause 203 
dementia (OR = 0.78, 95% CI = 0.65 to 0.93, P = 0.007). An unadjusted chi-square test showed 204 
64%% of people with AD had at least one e4 allele vs. 36% in the non-AD group.  205 
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 206 
APOE associations with biomarker values 207 
Several significant associations (at nominal p<0.05) were identified between APOE genotype 208 
status and biomarker values, as shown in Figure 1, which shows fully-adjusted estimates. 209 
Increasing e4 allele count associated with significant differences in several biomarker values 210 
(Supplementary Table S1). There were associations between e4 allele count vs. higher LDL, IGF-211 
1, sex hormone binding globulin (SHBG), total bilirubin, triphosphate levels, ApoB and total 212 
cholesterol. Negative associations were found between e4 genotype and lower high-density 213 
lipoprotein (HDL), haemoglobin A1c (HbA1c), lipoprotein A, phosphate, C-reactive protein 214 
(CRP), gamma glutamyl transferase (GGT), vitamin D, creatinine, urate, and urea. The largest 215 
effect sizes – based on fully-adjusted model results- were seen for total cholesterol (0.13 SDs 216 
per allele in the fully adjusted model), ApoB (0.20), CRP (-0.12) and LDL (0.15), with the rest 217 
<0.1SDs per e4 allele. There was no evidence of a significant fully adjusted association between 218 
e4 and oestradiol, aspartate transaminase (AST), albumin, testosterone and RF levels.  219 
 220 
[Figure 1 here] 221 
 222 
Significant associations were seen between e2 allele count vs. lower LDL, HDL, IGF-1, total 223 
bilirubin, direct bilirubin, vitamin D, CRP, cystatin C (CysC), ApoA, ApoB, creatinine and alkaline 224 
phosphatase (Figure 1). These are in the opposite directions of effect reported for the 225 
associations to the e4 allele (vs. e3/e3) as expected. Associations between APOE e2 and HbA1c, 226 
lipoprotein A, SHBG and triphosphate levels were also identified, however, these effects were in 227 
the same direction as e4. The largest effect sizes were for LDL (-0.46 SDs per allele in the fully-228 
adjusted model), triphosphate (0.13), ApoB (-0.61) and total cholesterol (-0.35), with the rest 229 
<0.1SDs per e2 allele. 230 
There were instances of significant association for e2 but not e4 vs. e3/e3. These were: 231 
negative associations between e2 vs. protein and aspartate aminotransferase levels, and 232 
positive association between e2 and testosterone. There was no statistically significant 233 
association between e2 count and oestradiol, phosphate, GGT, urate, urea and alanine 234 
aminotransferase levels (Supplementary Table S1). Both e4 and e2 were also found to associate 235 
with increased SHBG, decreased protein and increased triphosphate (vs. e3/e3).  236 
 237 
Sex-specific analyses 238 
There were instances of male/female sex vs. genotype interactions for several biomarkers 239 
(Supplementary Table S2). Out of 33 biomarkers, 16 showed some interaction (P<0.05): LDL, 240 
HDL, HbA1c, Oestradiol, RF, SHBG, Testosterone, protein, triphosphate, urate, ApoB, ApoA, total 241 
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cholesterol, AST and alanine transaminase (ALT). We provide complete sex-specific Z-score 242 
associations in Supplementary Table S3. Most of the significant associations in the collated 243 
analyses remained so in individual sexes. Certain associations were only significant in males: e4 244 
vs. oestradiol and calcium, and e2 vs. IGF-1, SHBG, testosterone and cystatin c.  245 
 246 
Sensitivity analyses 247 
All nominally significant associations survived correction for FDR. Results were unchanged in 248 
terms of effect size and P-value when individuals with incident dementia/AD were removed 249 
from analyses. When we added presence of any self-reported inflammatory condition, month of 250 
assessment, degree vs. not, underweight or obesity (vs. normal to overweight) to the final 251 
model, no results were meaningfully changed (Supplementary Table S4). Results were 252 
unchanged when we re-analysed all outcome variables with inverse-rank normalisation to 253 
avoid potential false positives caused by outlying values (prior to removing values >5SD from 254 
the mean), and when we used the maximum 40 PCs (vs. 5 reported). IGF-1 results were 255 
unchanged when we additionally controlled for all-cause cancer. As a check, we re-ran all final-256 
model tests as 0 vs. 1 allele, and 0 vs. 2 allele contrasts (rather than a 0/1/2 dose effect); results 257 
were consistently indicative of dose effects in the same direction.  258 
 259 
Discussion 260 
The APOE e4 allele is known to associate in UK Biobank with worse non-demented cognitive 261 
abilities [17], cerebrovascular health [3] and here clinically-ascertained AD/dementia risk 262 
(mostly; a small minority of cases were baseline self-report). In this study we found several 263 
significant associations per e4 allele on circulating biomarker levels (vs. neutral e3/e3). In many 264 
instances these were supported by corresponding associations between the putatively 265 
protective e2 genotype in the opposite direction as would be expected. Gaining a greater 266 
understanding of the biomarker profiles of individuals at genetic risk of AD may be useful in the 267 
future for earlier detection of AD and could potentially highlight pathways as therapeutic 268 
targets [11]. In some instances, the directions of effect for e4 (‘risk’) and e2 (‘protective’) alleles 269 
conflicted with what would be expected based on levels reported elsewhere in people with 270 
prevalent AD.  For example: lower levels of IGF-1 have previously associated with increased risk 271 
of AD and cognitive decline [6,25]. By contrast here we showed association between e4 and 272 
increased IGF-1, and between e2 genotype and lower IGF-1. This is surprising as IGF-1 273 
stimulates neurogenesis and promotes cell survival [26]. Previous reports could reflect some 274 
degree of reverse causality or bias in cross-sectional AD patient sample studies showing lower 275 
IGF-1 levels i.e. where disease onset affects biomarker health. 276 
Interpretation 277 
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Vitamin D 278 
Previous studies have reported APOE e4 association with higher vitamin D serum concentration 279 
[27] however here e4 associated with decreased, and e2 with increased vitamin D. In e4 280 
homozygotes, a higher vitamin D concentration has been associated with higher memory 281 
function, suggesting higher vitamin D levels could be protective for people at risk for AD [28].  282 
 283 
Lipids 284 
Investigations into the effect of differing cholesterol levels on cognitive decline and AD have 285 
produced conflicting results with both low and high cholesterol being associated [8,29–31]. The 286 
lack of consensus could be partially due to the smaller sample sizes previously used. The three 287 
APOE alleles encode for different ApoE protein isoforms with altered lipid interactions in serum; 288 
the e3 encoded protein isoform is associated with “normal” plasma lipid levels [32]. APOE e4 289 
and its associated higher LDL have been previously associated with early onset of AD [33] while 290 
e2 has protective effects on the concentrations of cholesterol, lipids and phospholipids [34].  291 
Here we reinforce those observations, particularly in the context of respective dose e2/e4 292 
protective vs. deleterious associations [5,8,34,35].  293 
It has been hypothesised that lipid metabolism is important in the pathophysiology of 294 
AD [11]. The significant associations between APOE genotype status and ApoA/ApoB support 295 
this. ApoA and ApoB proteins are major surface proteins of HDL and LDL, respectively [36]; 296 
previously ApoA has been associated with lower risk of cardiovascular disease [37], whereas, 297 
ApoB is reported to be proatherogenic [36]. We identified lower ApoA levels in e4 carriers and 298 
higher levels in e2 carriers; ApoA has reportedly neuroprotective effects by inhibiting β-amyloid 299 
plaque aggregation [36,38]. Our findings are supported by previous associations reported 300 
between decreased serum ApoA and increased AD risk [38]. With ApoB, we found e4 was 301 
associated with elevated levels of ApoB and e2 with lower levels of ApoB compared to e3. This 302 
is consistent with the direction of effect reported in most [10,33] but not all studies [36]. 303 
It is hypothesised APOE allele-encoded protein isoforms have different affinities for 304 
lipoproteins [39]. It has been difficult to define the exact effects of APOE genotype on 305 
lipoprotein A from previous studies’ many small sample sizes. Our data showed that both APOE 306 
e2 and e4 were significantly associated with decreased levels of lipoprotein A (vs. e3)[39]. 307 
Elevated levels of lipoprotein A are known to have a causal relationship with myocardial 308 
infarction, which has previously been associated with increased dementia risk [39]. The 309 
influence of lower lipoprotein A on the pathophysiology of AD remains unclear. 310 
APOE genotype status may modify the effect of sex hormones on dementia symptoms 311 
[40]. We did not find any evidence for a significant association between APOE genotype and 312 
oestradiol in the whole sample, although in males e4 associated with lower levels. Oestradiol 313 
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has suggested overall neuroprotective effects; however, evidence is conflicting, and this 314 
relationship is not fully understood [40]. We found an association between APOE e2 and higher 315 
testosterone levels, specific to males.  There is conflicting evidence regarding the effect of 316 
testosterone on AD risk [41,42]; some cross-sectional studies report lower levels of 317 
testosterone in AD patients vs. healthy controls [42],consistent with our findings as e2 is 318 
associated with decreased AD risk [1]. 319 
 320 
Inflammation 321 
The underlying pathophysiology of AD has been suggested to be at least partially influenced by 322 
neuroinflammation [43]. Serum CRP levels are a marker for inflammation but the evidence for 323 
association with AD risk is conflicting. Interactions between APOE e4 and elevated CRP have 324 
been reported to associate with early onset of AD [44]. However, consistent with our findings e4 325 
has been associated with lower CRP levels, and e2 with higher CRP levels [10,45]. Further 326 
research is required to elucidate the effects of CRP levels on the pathophysiology of AD, 327 
particularly given it is a marker of acute rather than chronic inflammation [43]. Another 328 
inflammatory marker associated with increased risk of AD is raised GGT [46]. We identified 329 
lower levels of GGT in e4 carriers: this may reflect bias in cross-sectional studies of GGT and AD.   330 
Alkaline phosphatase may have some involvement in the inflammatory/AD process [47]. 331 
We identified lower levels of alkaline phosphatase in e4 carriers and elevated levels in e2 332 
carriers. It has been suggested that alkaline phosphatase could potentially be used as a therapy 333 
to reduce neuroinflammation in AD [47]; our findings may support this but more in depth 334 
investigations are required. 335 
CysC, typically a marker of kidney dysfunction, is also involved in modulation of 336 
inflammatory responses and reported to have neuroprotective effects in AD as it co-localizes 337 
with β-amyloid and inhibits oligomerization [48]. We found that e4 associated with lower CysC 338 
and e2 with higher CysC levels compared to e3. Lower baseline CysC has been reported to 339 
precede AD onset in an 11-year longitudinal study of non-demented elderly men at baseline; in 340 
one small study (N=82) [49] which suggested the finding may be due to attrition bias because 341 
higher CysC is a risk factor for cardiovascular disease and earlier mortality. Our findings 342 
potentially lend support to low CysC serum levels as an AD risk factor.  343 
 344 
Other biomarkers 345 
We report suggestive association between e4 and lower phosphate levels, potentially 346 
contradicting prior research showing association between (age-dependent) higher serum 347 
phosphorous and incident dementia [50]. We found significant associations between e4 and 348 
higher total bilirubin and urea, and lower direct bilirubin, urate, creatinine, calcium, and alanine 349 
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aminotransferase. In the whole sample analysis, we found evidence of associations between e2 350 
and higher direct bilirubin, creatinine and aspartate aminotransferase, and lower total bilirubin 351 
and albumin. Both e4 and e2 associated in same direction with HbA1c, SHBG, protein and 352 
triphosphate. This is unexpected: e4 and e2 tend to show opposing effects regarding AD. We 353 
found proportionally moderate evidence of interaction between sex, genotype and biomarker; 354 
this is a significant area of research and warrants further study along with investigation age- 355 
and multimorbidity-related interactions [12]. 356 
 357 
Limitations and future research 358 
A limitation of UK Biobank is that participants are overall likely to have fewer health conditions, 359 
be better educated, of older age, female, and living in less socio-economically deprived areas 360 
than the general population [13]. This study was conducted in individuals of White European 361 
ancestry only and so these results may not be generalizable to a more mixed population. 362 
Findings may not be truly representative of the effects of APOE genotype in the wider UK 363 
population [13]. There may be conflicting biases at play in at least some of the results. For 364 
example, confounding effects may exist where e4 carriers are of poorer health, affecting their 365 
lifestyle and in turn influencing biomarker values, or by contrast selection bias, where the e4 366 
carriers here are of particularly good health relative to the general population.  367 
Although this study reports significant associations between serum biomarkers and 368 
APOE genotype, which could influence the risk of AD, these alleles are unlikely to be entirely 369 
responsible [1].  Associations may to some extent reflect early prodromal AD; future study may 370 
investigate biomarkers in AD-by-proxy (i.e. family history) cases. Some biomarker levels may 371 
only be pathogenic in combination with other biomarkers [8]. Some of the biomarkers may be 372 
influenced by environmental factors such as seasonality, although this should to some extent 373 
average out; sensitivity analyses showed no evidence of confounding. The effect sizes reported 374 
here are in many cases small and the results require replication; the clinical applicability of 375 
these findings remains unclear. It is not necessarily possible to identify the exact biological 376 
pathways involved in the pathophysiology of AD from these analyses. Further work is required 377 
to investigate the underlying pathways to identify processes which could be modified or 378 
targeted to decrease the risk of AD, including longitudinal biomarker data [12,35]. Future 379 
research e.g. using Mendelian randomization may investigate whether pharmaceutically 380 
altering serum biomarker levels or implementing lifestyle changes to manage these biomarkers 381 
may be beneficial to individuals at greater risk of developing AD.  382 
 383 
Conclusion 384 
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The exact influence of APOE on AD and dementia pathophysiology is unclear. Through this study 385 
we have identified associations between the high-risk AD gene locus APOE and a range of serum 386 
blood biomarkers in UK Biobank. These associations highlight potential pathways involved in 387 
the development of cognitive impairment and have potential to lead to earlier detection of AD 388 
risk through the analysis of biomarkers and APOE genotype. 389 
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Table 1: Baseline descriptive values.  638 
 Mean (SD) Median Min Max 
Age 56.9 (8.0) 58 39 73 
Townsend 
deprivation score 
-1.57 (2.9) 2.35 -6.26 10.8 
All-cause dementia Cases N (%) Controls N (%) 
 1,852 (0.47%) 393,917 (99.53%) 
Alzheimer’s disease Cases N (%) Controls N (%) 
 722 (0.18%)  395,047 (99.82%) 
 Male Female 
Sex 181,000  
(45.7%) 
214,771  
(54.3%) 
 e3/e3 e3/e4 e4/e4 e3/e2 e2e2 
APOE genotype 230,094 
(59.7%) 
94,395 
(24.5%) 
9,518 
(2.4%) 
49,082 
(12.7%) 
2,557 
(0.6%) 
 Non-smoker Previously smoked Current smoker 
Smoking status 216,094 
(54.8%) 
138,744 
(35.2%) 
39,580 
(10%) 
 No Yes 
CHD 466,843 
(96.5%) 
16,920 
(3.5%) 
High BP 381,072 
(78.8%) 
102,691 
(21.2%) 
Type 2 diabetes 376,233 
(95.3%) 
18,702 
(4.7%) 
Medication 329,322 
(83.4%) 
65,634 
(16.6%) 
Biomarkers (not 
standardised) 
Mean Standard 
deviation 
Min Max N 
Low-density 
lipoprotein 3.6 0.9 0.5 7.9 376,668 
High-density 
lipoprotein 1.5 0.4 0.2 3.4 345,315 
Insulin-growth like 
factor-1 21.4 5.5 1.4 49.6 375,135 
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Hemoglobin A1C 35.6 5.1 15.0 68.1 374,702 
Lipoprotein A 44.1 49.5 3.8 189.0 300,249 
Oestradiol 71.6 173.8 8.5 1313.3 349,998 
Phosphate 1.2 0.2 0.4 2.0 344,894 
Rheumatoid factor 4.4 4.9 3.2 47.4 374,322 
Sex hormone-
binding globulin 51.4 26.4 0.4 189.3 341,418 
Total Bilirubin 9.0 3.9 1.1 31.2 374,181 
Direct bilirubin 1.8 0.7 1.0 6.0 320,111 
Testosterone 6.5 6.0 0.4 36.7 341,975 
Protein 72.4 4.0 36.3 92.5 345,085 
Triphosphate 1.7 1.0 0.2 6.9 375,888 
Urate 309.1 79.9 89.1 708.8 376,905 
Vitamin D 49.9 20.8 10.0 154.0 360,598 
C-reactive protein 2.3 3.0 0.1 24.2 373,817 
Gamma-
glutamyltransferase 34.9 28.1 5.0 241.7 374,958 
Cystatin C 0.9 0.1 0.3 1.8 376,382 
ApoB 1.0 0.2 0.4 2.0 375,576 
ApoA 1.5 0.3 0.4 2.5 343,506 
Creatinine 72.0 14.5 10.8 161.4 376,640 
Total cholesterol 5.7 1.1 1.4 11.4 377,349 
Calcium 2.4 0.1 1.2 2.8 345,223 
Urea 5.4 1.3 0.8 12.3 376,453 
Aspartate 
transaminase (AST) 25.8 7.5 3.3 78.7 374,496 
Alanine 
transaminase (ALT) 23.0 11.6 3.0 93.7 375,656 
Alkaline 
phosphatase 83.1 22.9 8.0 215.0 376,658 
Albumin 45.2 2.6 18.9 58.2 345,558 
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Figure 1: linear 639 
regression fully-640 
adjusted 641 
standardized 642 
betas comparing 643 
APOE e4 and e2 644 
genotypes (per 645 
allele) vs. neutral 646 
e3/e3, on 647 
biomarker 648 
values. P<0.05, 649 
**P<0.001 650 
